Enzon Pharmaceuticals
(NDAQ:ENZN) shareholders may soon be rewarded after a large shareholder
expressed concerns regarding a “troubling disconnect” in the stock.
DellaCamera Capital, which owns 5.2% of the company, requested that the
company hire an advisor to analyze various financial and structural
options and implement a cohesive financial plan of action that would
deliver increased value to shareholders.
“In our opinion, Enzon’s current stock price of $9.75 represents a significant discount to the intrinsic value of
the Company and in no way reflects the tremendous embedded optionality
associated with Enzon’s R&D pipeline and technology platform,” said
portfolio manager Richard Mansouri. “It is our belief that the
corporate structure and operational complexity of Enzon have made it
difficult for the investment community to accurately assess the inherent value of the Company.”
The activist hedge fund pointed out that a share price of $9.75
implies a shocking negative valuation of -$263.5 million for the
company’s R&D operations that, in reality, show promise. Enzon has
four products on the market that will generate an estimated $100
million in revenue in 2007. A reasonable sales multiple of 3.5x yields
a value of $350 million for the marketed products alone. Add in the
revenues from royalties and contracted manufacturing and you get an
additional $440 million in value.
So, why is there such a value disconnect? Well, DellaCamera insists
that it can be traced to the company’s complex structure. Currently,
Enzon operates in two businesses: (1) a commercial business comprised
of marketed products, royalties, and contract manufacturing; and (2)an
R&D organization and technology platform. The profitability of the
commercial operations is being completely obscured by the expenses
associated with advancing the company’s clinical and pre-clinical
trials. This complexity has also led to operating inefficiencies that
have resulted in runaway expenses.
In the end, DellaCamera insists that the company should work to
simplify its message to investors by consolidating its operations or
taking other measures to unlock value. To this end, they requested that
the company hire an advisor in order to explore the best options.
Combined, these factors make ENZN a stock worth watching!
Related Companies
Amgen Inc. (AMGN)
Pfizer Inc. (PFE)
Merck & Co. (MRK)